Report Categories Report Categories

Report Categories

industry Category

All

Total: 2 records, 1 pages

Global Treating Chronic Myeloid Leukemia by Phase Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 01 Oct 2024

date Pharma & Healthcare

new_biaoQian Treating Chronic Myeloid Leukemia by Phase

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.

USD3480.00

Add To Cart

Add To Cart

Global Treating Chronic Myeloid Leukemia by Phase Supply, Demand and Key Producers, 2024-2030

date 01 Oct 2024

date Pharma & Healthcare

new_biaoQian Treating Chronic Myeloid Leukemia by Phase

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.

USD4480.00

Add To Cart

Add To Cart

industry 01 Oct 2024

industry Pharma & Healthcare

new_biaoQian Treating Chronic Myeloid Leukemia by Phase

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.

USD3480.00

addToCart

Add To Cart

industry 01 Oct 2024

industry Pharma & Healthcare

new_biaoQian Treating Chronic Myeloid Leukemia by Phase

The treatment of chronic myeloid leukemia (CML) is structured around the disease's phases: chronic, accelerated, and blast. In the chronic phase, first-line therapy typically involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib. If CML progresses to the accelerated phase, treatment may shift to a different TKI, combination therapies, or clinical trials to manage resistance. In the blast phase, characterized by acute leukemia-like features, more intensive treatments such as chemotherapy or stem cell transplantation are often required.

USD4480.00

addToCart

Add To Cart